MRC/BHF Heart Protection Study

Congenital Heart Disease White Matter Protection in Congenital Heart Surgery

White matter protection in congenital heart surgery.

BACKGROUND Neurodevelopmental delays in motor skills and white matter (WM) injury have been documented in congenital heart disease and after pediatric cardiac surgery. The lack of a suitable animal model has hampered our understanding of the cellular mechanisms underlying WM injury in these patients. Our aim is to identify an optimal surgical strategy for WM protection to reduce neurological in...

Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study

Background-Low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol are

Comparative experimental study of myocardial protection with crystalloid solutions for heart transplantation.

BACKGROUND There is a growing need to improve myocardial protection, which will lead to better performance of cardiac operations and reduce morbidity and mortality. Therefore, the objective of this study was to compare the efficacy of myocardial protection solution using both intracellular and extracellular crystalloid type regarding the performance of the electrical conduction system, left ven...

The Heart Protection Study: high-risk patients benefit from statins, regardless of LDL-C level.

The landmark Heart Protection Study (Lancet 2002; 360:7-22) found benefit in treating subjects at high risk of a coronary event with simvastatin 40 mg daily, regardless of baseline low-density lipoprotein cholesterol level and in all subgroups, including women and the elderly. The study found no benefit of simvastatin therapy in preventing noncardiac events (eg, dementia, osteoporotic fractures...